Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial

CCR5 Expression Levels Influence NFAT Translocation, IL-2 Production, and Subsequent Signaling Events during T Lymphocyte Activation

(2014) J. F. Camargo et al.   JOURNAL OF IMMUNOLOGY

Maraviroc-induced decrease in circulating bacterial products is not linked to an increase in immune activation in HIV-infected individuals

(2013) C. Psomas et al.   BLOOD

The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial

(2013) P. W. Hunt et al.   BLOOD

Unknown

(2013) Samantha Westrop et al.   MOLECULAR MEDICINE

Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial

(2013) Stefano Rusconi et al.   PLoS One

The intensity of immune activation is linked to the level of 
CCR5 expression in human immunodeficiency virus type 
1-infected persons

(2012) Pierre Portales et al.   IMMUNOLOGY

A Pilot Trial of Adding Maraviroc to Suppressive Antiretroviral Therapy for Suboptimal CD4+ T-Cell Recovery Despite Sustained Virologic Suppression: ACTG A5256

(2012) T. J. Wilkin et al.   JOURNAL OF INFECTIOUS DISEASES

Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease

(2012) Ran Reshef et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort

(2011) Steven F.L. van Lelyveld et al.   AIDS

Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice

(2011) J. Symons et al.   CLINICAL MICROBIOLOGY AND INFECTION

The Relationship of CCR5 Antagonists to CD4+ T-Cell Gain: A Meta-Regression of Recent Clinical Trials in Treatment-Experienced HIV-Infected Patients

(2011) Timothy J. Wilkin et al.   HIV CLINICAL TRIALS

Decreased Thymic Output Accounts for Decreased Naive T Cell Numbers in Children with Down Syndrome

(2011) Beatrijs L. P. Bloemers et al.   JOURNAL OF IMMUNOLOGY

European guidelines on the clinical management of HIV-1 tropism testing

(2011) LPR Vandekerckhove et al.   LANCET INFECTIOUS DISEASES

Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected

(2011) Carolina Gutiérrez et al.   PLoS One

A Novel Chemokine-Receptor-5 (CCR5) Blocker, SCH532706, Has Differential Effects on CCR5+CD4+ and CCR5+CD8+ T Cell Numbers in Chronic HIV Infection

(2010) Sarah L. Pett et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection

(2010) David A. Cooper et al.   JOURNAL OF INFECTIOUS DISEASES

The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5

(2009) Yea-Lih Lin et al.   AIDS

Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery

(2009) Olena Stepanyuk et al.   AIDS

Incomplete Peripheral CD4+Cell Count Restoration in HIV‐Infected Patients Receiving Long‐Term Antiretroviral Treatment

(2009) Colleen F. Kelley et al.   CLINICAL INFECTIOUS DISEASES

Poor Initial CD4+ Recovery With Antiretroviral Therapy Prolongs Immune Depletion and Increases Risk for AIDS and Non-AIDS Diseases

(2009) Jason V Baker et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Life after the thymus: CD31+ and CD31- human naive CD4+ T-cell subsets

(2008) S. Kohler et al.   BLOOD

Clinical Outcome of HIV-Infected Antiretroviral-Naive Patients With Discordant Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy

(2008) Ruimin Tan et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1–infected individuals

(2008) Sunil K Ahuja et al.   NATURE MEDICINE

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

(2008) Roy M. Gulick et al.   NEW ENGLAND JOURNAL OF MEDICINE